Journal Article

Analyses of bronchial bulky DNA adduct levels and <i>CYP2C9</i>, <i>GSTP1</i> and <i>NQO1</i> genotypes in a Hungarian study population with pulmonary diseases

Shogo Ozawa, Bernadette Schoket, L.Patrice McDaniel, Yong-Ming Tang, Christine B. Ambrosone, Szilárd Kostic, István Vincze and Fred F. Kadlubar

in Carcinogenesis

Volume 20, issue 6, pages 991-995
Published in print June 1999 | ISSN: 0143-3334
Published online June 1999 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/20.6.991
Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

Carcinogen–DNA adducts may represent an intermediate end-point in the carcinogenic cascade and may reflect exposure to chemical carcinogens, as well as susceptibility and, ultimately, cancer risk. Interindividual variability in activity of enzymes involved in the metabolism of polycyclic aromatic hydrocarbons to mutagenic diol epoxides may predict adduct levels and, indirectly, lung cancer risk. Using 32P-postlabeling methods, the levels of bulky DNA adducts were determined in macroscopically normal bronchial tissues obtained from resected lobes of 143 Hungarian patients with lung malignancy and other pulmonary conditions. DNA from normal tissue was also evaluated for polymorphisms in cytochrome P450 2C9 (CYP2C9) at two sites, codons 144 (Arg/Cys) and 359 (Ile/Leu), for glutathione S-transferase P1 (GSTP1) at codon 105 and for NAD(P)H:quinone oxidoreductase (NQO1) at codon 187 (Pro/Ser). Using the Mann–Whitney U-test and analysis of variance, levels of adducts were evaluated in relation to variant genotypes, separately for smokers and non-smokers. As previously reported, bulky DNA adduct levels in smokers (n = 104) were estimated to be 54% higher than in non-smokers (n = 39) (8.6 ± 4.2 versus 5.6 ± 3.3 per 108 nucleotides, respectively, P < 0.01). Adduct levels were 16–29% higher in individuals with the homozygous Ile359/Ile359 CYP2C9 allele than in those heterozygous for the variant allele (Ile359/Leu359) [8.8 ± 4.3 (n = 84) versus 7.6 ± 3.5 (n = 20) for smokers and 5.8 ± 3.5 (n = 32) versus 4.5 ± 1.3 (n = 7) for non-smokers], although differences were not statistically significant. There were no clear differences in adduct levels in relation to genotypes of NQO1 or GSTP1. Although numbers of patients in this study are large in relation to many studies of carcinogen–DNA adducts, it is still possible that significant differences were not noted for polymorphisms in xenobiotic metabolizing enzymes due to relatively small numbers in stratified data.

Keywords: anti-BPDE, anti-benzo[a]pyrene 7,8-diol 9,10-epoxide; B[a]P, benzo[a]pyrene; CYP, cytochrome P450; GST, glutathione S-transferase; NQO1, NAD(P)H:quinone oxidoreductase; PAH, polycyclic aromatic hydrocarbon.

Journal Article.  4414 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.